Octreotide Acetate Articles

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir

18 February 2013

Lutathera first MNM theragnostic drug, enters Ph III in cancer patients with midgut carcinoid

20 September 2012

Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal

27 January 2010

Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes

26 January 2010

Novartis delivers strong new product momentum; raises full-year 2009 guidance

22 October 2009

Lotus to acquire gastric ulcer drug Yipubishan from Beijing Yipuam Bio

23 February 2009

Novartis drug slows 69% of GI tumors

26 January 2009

77% of patients on RAD001 achieve stable pancreatic NET tumors

22 September 2008

ESMO hears strong data on Novartis' everolimus in kidney cancer and NET tumors

22 September 2008

US FDA posts first quarterly report of potential safety issues, cites eight drugs

15 September 2008

Vaccines and diagnostics help Swiss major Novartis beat expectations

28 April 2008

Novartis' 4th-qtr profits fall 45%; but full-year 2007 income climbs to $12B

21 January 2008

Octreotide implant sees 6-month efficacy

10 December 2007

Novartis' 2nd-qrt just beats forecasts, with sales up 10%, profits 18% higher

23 July 2007

13 new drugs added to Japan's NHI list

19 March 2007

Expanded use for Novartis' Sandostatin LAR in UK

5 July 2004

Novartis' Sandostatin LAR OKed in Japan

3 May 2004

Novartis beats firstquarter forecasts as sales climb 17%, losing

12 April 2000

Novartis third-quarter sales above forecasts, though pharmaceuticals remain

21 October 1999

Novartis highlights clinical projects to turn around fortunes at its pharma

27 September 1999

Unspectacular first-half sales for Novartis, third-quarter pharma growth to

15 July 1999

Novartis Compares Growth Hormone Therapies

17 June 1999

Novartis highlights four new products at annual results meeting

18 March 1999

Novartis building on strong fundamentals, having achieved merger targets

16 March 1999

US FDA makes progress, says their own product review record for 1998

29 January 1999

Novartis 1998 sales down on forecasts

21 January 1999

Novartis' Sandostatin LAR Depot Approved By FDA

2 December 1998

Pharma Sales Give Novartis Boost

22 October 1998

Novartis Restructures After Disappointing First Half

1 September 1998

Novartis First Half Sales Under Expectations

16 July 1998

Novartis Files NDA For Sandostatin LAR

4 June 1998

Sensus Corp On Route To Success With GHAs?

12 February 1998

Novartis Launches Sandostatin LAR In First Market

18 December 1997

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Sandoz Demergers To Focus On Pharmaceuticals

3 April 1995

Sandoz' 1994 Sales Advance 11%

23 January 1995

3% Increase In Sales For Sandoz

31 October 1994

Improvement At Sandoz in 1994 1st Half

12 September 1994

SOLID VOLUME GROWTH HELPS SANDOZ' SALES

25 July 1994

OCTREOSCAN APPROVED IN USA

13 June 1994

PHARMA SALES DRIVE SANDOZ IN 1993

31 January 1994

SUSTAINABLE EARNINGS GROWTH FOR SANDOZ

16 August 1993

SANDOZ POSTS STRONG NET INCOME

26 July 1993

MALLINCKRODT'S OCTREOSCAN

7 June 1993

BREAST CANCER US RESEARCH UPDATE

26 April 1993

1992 NET PROFITS SURGE 34% AT SANDOZ

5 April 1993

NDA FOR MALLINCKRODT

2 November 1992

THERAPEUTIC PEPTIDE MARKET

6 July 1992

SANDOSTATIN IN DIABETES

20 January 1992

Showing 1-50 of 50 articles

Go to beginningPrevious
  • 1
NextGo to end